What is the recommended application for this antibody?

The Mouse Anti-ACMSD Recombinant Antibody (V2-12501) is validated for use in Western Blot (WB) and ELISA. For other applications, we recommend referring to the Certificate of Analysis (COA) for recommended starting dilutions, though optimal dilutions should be determined by the end-user.

Does this antibody cross-react with other species?

This antibody is specific to Human ACMSD. If you need to use this antibody for a species that is not listed on the datasheet, we recommend checking the sequence alignment of the immunogen with the protein of interest in your target species. You can also contact our technical support for further assistance.

Mouse Anti-ACMSD Recombinant Antibody (V2-12501) (CBMAB-0991-CN)

See all ACMSD antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

V2-12501

Application

WB, ELISA

Immunogen

ACMSD (NP_612199, aa. 179-278) partial recombinant protein with GST tag.

Specificity

Human

Antibody Isotype

IgG2b

Clonality

Monoclonal

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Application	Note
WB	1-5 µg/ml

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Buffer

PBS, pH 7.4

Preservative

None

Concentration

Batch dependent

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

More Infomation

Target

Full Name

aminocarboxymuconate semialdehyde decarboxylase

Introduction

The neuronal excitotoxin quinolinate is an intermediate in the de novo synthesis pathway of NAD from tryptophan, and has been implicated in the pathogenesis of several neurodegenerative disorders. Quinolinate is derived from alpha-amino-beta-carboxy-muconate-epsilon-semialdehyde (ACMS). ACMSD (ACMS decarboxylase; EC 4.1.1.45) can divert ACMS to a benign catabolite and thus prevent the accumulation of quinolinate from ACMS. The protein converts alpha-amino-beta-carboxymuconate-epsilon-semialdehyde (ACMS) to alpha-aminomuconate semialdehyde (AMS). ACMS can be converted non-enzymatically to quinolate (QA), a key precursor of NAD, and a potent endogenous excitotoxin of neuronal cells which is implicated in the pathogenesis of various neurodegenerative disorders. In the presence of ACMSD, ACMS is converted to AMS, a benign catabolite. ACMSD ultimately controls the metabolic fate of tryptophan catabolism along the kynurenine pathway.

Entrez Gene ID

130013

UniProt ID

Q8TDX5

Alternative Names

2-amino-3-carboxymuconate-6-semialdehyde decarboxylase; picolinate carboxylase; EC 4.1.1.45

Function

Converts alpha-amino-beta-carboxymuconate-epsilon-semialdehyde (ACMS) to alpha-aminomuconate semialdehyde (AMS). ACMS can be converted non-enzymatically to quinolate (QA), a key precursor of NAD, and a potent endogenous excitotoxin of neuronal cells which is implicated in the pathogenesis of various neurodegenerative disorders. In the presence of ACMSD, ACMS is converted to AMS, a benign catabolite. ACMSD ultimately controls the metabolic fate of tryptophan catabolism along the kynurenine pathway.

Biological Process

Negative regulation of quinolinate biosynthetic process
Picolinic acid biosynthetic process
Regulation of 'de novo' NAD biosynthetic process from tryptophan
Secondary metabolic process
Tryptophan catabolic process

Cellular Location

Cytosol; Cytoplasm

Chang, K. H., Chen, C. M., Chen, Y. C., Fung, H. C., & Wu, Y. R. (2019). Polymorphisms of ACMSD-TMEM163, MCCC1, and BCKDK-STX1B are not associated with Parkinson’s disease in Taiwan. Parkinson’s Disease, 2019.

Palzer, L., Bader, J. J., Angel, F., Witzel, M., Blaser, S., McNeil, A., ... & Meyer-Ficca, M. L. (2018). Alpha-amino-beta-carboxy-muconate-semialdehyde decarboxylase controls dietary niacin requirements for NAD+ synthesis. Cell reports, 25(5), 1359-1370.

Thirtamara-Rajamani, K., Li, P., Escobar Galvis, M. L., Labrie, V., Brundin, P., & Brundin, L. (2017). Is the enzyme ACMSD a novel therapeutic target in Parkinson’s disease?. Journal of Parkinson's disease, 7(4), 577-587.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-ACMSD Recombinant Antibody (V2-12501)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry